Stockreport

BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial

BiondVax Pharmaceuticals Ltd. - American Depositary Shares  (BVXV) 
US:NASDAQ Investor Relations: biondvax.com/investors
PDF JERUSALEM, March 19, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoin [Read more]